Obese patients have impaired vasodilator reactivity and increased endothelin (ET)-1-mediated vasoconstriction, two abnormalities contributing to vascular dysfunction. Obestatin, a product of the ghrelin gene, in addition to favorable effects on glucose and lipid metabolism, has shown nitric oxide (NO)-dependent vasodilator properties in experimental models. Given these premises, we compared the effects of exogenous obestatin on forearm flow in lean and obese subjects and assessed its influence on ET-1-dependent vasoconstrictor tone in obesity. In both lean and obese participants, infusion of escalating doses of obestatin resulted in a progressive increase in blood flow from baseline (both P<0.001); this vasodilation was predominantly mediated by enhanced NO activity, because L-NMMA markedly blunted the flow response to obestatin in both groups (both P<0.05 vs. saline). In obese subjects, antagonism of ETA receptors by BQ-123 increased forearm flow during saline (P<0.001), but did not induce additional vasodilation (P>0.05) during obestatin. Circulating obestatin levels were not different between lean and obese participants (P=0.41). Our findings indicate that obestatin causes NO-dependent vasodilation in the human circulation. This effect is preserved in obesity, where it is accompanied by reduced ET-1-mediated vasoconstriction. These latter observations make obestatin a promising target for vascular prevention in obesity and diabetes.

Schinzari, F., Veneziani, A., Mores, N., Barini, A., Di Daniele, N., Cardillo, C., et al. (2017). Vascular Effects of Obestatin in Lean and Obese Subjects. DIABETES, db161067 [10.2337/db16-1067].

Vascular Effects of Obestatin in Lean and Obese Subjects

DI DANIELE, NICOLA;TESAURO, MANFREDI
2017-02-07

Abstract

Obese patients have impaired vasodilator reactivity and increased endothelin (ET)-1-mediated vasoconstriction, two abnormalities contributing to vascular dysfunction. Obestatin, a product of the ghrelin gene, in addition to favorable effects on glucose and lipid metabolism, has shown nitric oxide (NO)-dependent vasodilator properties in experimental models. Given these premises, we compared the effects of exogenous obestatin on forearm flow in lean and obese subjects and assessed its influence on ET-1-dependent vasoconstrictor tone in obesity. In both lean and obese participants, infusion of escalating doses of obestatin resulted in a progressive increase in blood flow from baseline (both P<0.001); this vasodilation was predominantly mediated by enhanced NO activity, because L-NMMA markedly blunted the flow response to obestatin in both groups (both P<0.05 vs. saline). In obese subjects, antagonism of ETA receptors by BQ-123 increased forearm flow during saline (P<0.001), but did not induce additional vasodilation (P>0.05) during obestatin. Circulating obestatin levels were not different between lean and obese participants (P=0.41). Our findings indicate that obestatin causes NO-dependent vasodilation in the human circulation. This effect is preserved in obesity, where it is accompanied by reduced ET-1-mediated vasoconstriction. These latter observations make obestatin a promising target for vascular prevention in obesity and diabetes.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/09 - Medicina Interna
English
Con Impact Factor ISI
Schinzari, F., Veneziani, A., Mores, N., Barini, A., Di Daniele, N., Cardillo, C., et al. (2017). Vascular Effects of Obestatin in Lean and Obese Subjects. DIABETES, db161067 [10.2337/db16-1067].
Schinzari, F; Veneziani, A; Mores, N; Barini, A; DI DANIELE, N; Cardillo, C; Tesauro, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/179918
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact